Skip to main content
Premium Trial:

Request an Annual Quote

AxCell s Becker Tapped to Run Cytogen as CEO Steps Down

For an updated version of this article, click here.

 

NEW YORK, Dec. 17 - Cytogen today said it has tapped AxCell chief Michael Becker to replace Joseph Reiser, who stepped down as president and CEO "for personal reasons" this afternoon.

 

Additionally, Lawrence Hoffman has quit as vice president and CFO, and Thu Dang, Cytogen's director of finance and 14-year veteran of the company, has been promoted to VP of finance.

 

It was not immediately clear whether Becker's ascension will affect AxCell, or if he will run both firms.

 

"As we look ahead to the next phase in Cytogen's evolution, I believe it is appropriate that Michael take on an expanded role as CEO," said Reiser, who will stay on as a board member.

 

Beside running AxCell, Becker was VP of business development and investor relations at Cytogen, where he has now been named to the board.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.